




Belgian Cancer Registry

CANCER FACT SHEET 2023

OESOPHAGEAL CANCER

ICD-10 C15-C16.0



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2023, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

ADC: Adenocarcinomas

SCC: Squamous cell carcinomas



1. CANCER INCIDENCE	5
1.1. Oesophageal cancer incidence: by region	5
1.1.1. Oesophageal cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023	5
1.2. Oesophageal cancer incidence: by tumour stage	7
1.2.1. Oesophageal cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	7
1.2.2. Oesophageal cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	7
1.2.3. Oesophageal cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	8
1.3. Oesophageal cancer incidence: by tumour type	9
1.3.1. Oesophageal cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	9
1.4. Oesophageal cancer incidence: by tumour sub-location	9
1.4.1. Oesophageal cancer incidence by sub-location, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	9
1.5. Oesophageal cancer incidence: by tumour type and tumour stage	10
1.5.1. Oesophageal cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	10
1.6. Oesophageal cancer incidence: by tumour sub-location and tumour stage	11
1.6.1. Oesophageal cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	11
1.7. Oesophageal cancer incidence: by tumour sub-location and tumour type	13
1.7.1. Oesophageal cancer incidence by sub-location, type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	13
2. CANCER INCIDENCE TRENDS	14
2.1. Oesophageal cancer incidence trends: by region	14
2.1.1. Oesophageal cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023	14
2.1.2. Oesophageal cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023	16
2.2. Oesophageal cancer incidence trends: by tumour stage	17
2.2.1. Oesophageal cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards ...	17
2.3. Oesophageal cancer incidence trends: by tumour type	19
2.3.1. Oesophageal cancer incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards ...	19
2.4. Oesophageal cancer incidence trends: by tumour sub-location	20
2.4.1. Oesophageal cancer incidence trends by sub-location and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards ...	20

2.5. Oesophageal cancer incidence trends: by age group.....	22
2.5.1. Oesophageal cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	22
2.5.2. Oesophageal cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	23
3. CANCER PREVALENCE.....	24
3.1. Oesophageal cancer prevalence: by region.....	24
3.1.1. Oesophageal cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023	24
4. CANCER SURVIVAL.....	25
4.1. Oesophageal cancer survival: by region	25
4.1.1. Oesophageal cancer survival by region, sex and age group: number at risk and net survival probabilities, 2014-2023	25
4.2. Oesophageal cancer survival: by tumour stage	27
4.2.1. Oesophageal cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2014-2023	27
4.2.2. Oesophageal cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2014-2023	28
4.2.3. Oesophageal cancer survival by stage and sex: number at risk and net survival probabilities, 2014-2023	29
4.3. Oesophageal cancer survival: by tumour type and tumour stage	30
4.3.1. Oesophageal cancer survival by type, stage and sex: number at risk and net survival probabilities, 2014-2023	30
5. CANCER SURVIVAL TRENDS.....	33
5.1. Oesophageal cancer survival trends: by tumour stage.....	33
5.1.1. Oesophageal cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2023	33
5.2. Oesophageal cancer survival trends: by tumour type and tumour stage.....	35
5.2.1. Oesophageal cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2023.....	35
6. CANCER MORTALITY	39
6.1. Oesophageal cancer mortality: by region.....	39
6.1.1. Oesophageal cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021	39
7. CANCER MORTALITY TRENDS.....	41
7.1. Oesophageal cancer mortality trends: by region	41
7.1.1. Oesophageal cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	41
7.1.2. Oesophageal cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	42

1. CANCER INCIDENCE



1.1. Oesophageal cancer incidence: by region

1.1.1. *Oesophageal cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023*

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Males																						
Belgium	0	0	0	0	0	2	1	3	10	27	53	124	150	218	228	190	125	60	15	5	1,211	22.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.3]	[0.8]	[2.6]	[7.2]	[13.4]	[30.8]	[40.0]	[68.5]	[85.6]	[93.5]	[100.1]	[75.3]	[47.9]	[82.5]	[21.0]	(20.9; 23.4)
Brussels	0	0	0	0	0	0	0	0	2	0	3	10	6	5	15	10	6	4	1	0	62	16.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[4.3]	[0.0]	[7.3]	[28.2]	[20.8]	[23.4]	[89.2]	[79.2]	[74.6]	[80.0]	[43.4]	[0.0]	[10.2]	(12.1; 20.4)
Flanders	0	0	0	0	0	0	0	0	3	18	29	62	82	130	130	123	82	41	9	5	714	21.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.4]	[8.5]	[12.7]	[25.6]	[35.8]	[66.4]	[79.2]	[94.4]	[99.5]	[76.2]	[43.3]	[125.9]	[21.3]	(19.5; 22.5)
Wallonia	0	0	0	0	0	2	1	3	5	9	21	52	62	83	83	57	37	15	5	0	435	25.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[0.8]	[2.6]	[4.3]	[7.6]	[16.8]	[41.7]	[53.0]	[82.3]	[97.2]	[94.5]	[107.6]	[71.7]	[60.8]	[0.0]	[24.2]	(23.2; 28.1)
Females																						
Belgium	0	0	0	0	0	1	1	1	1	6	19	27	50	74	54	71	45	41	22	7	420	6.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.3]	[0.3]	[1.6]	[4.9]	[6.8]	[13.1]	[21.9]	[18.2]	[28.9]	[25.8]	[30.6]	[31.0]	[33.6]	[7.1]	(5.8; 7.1)
Brussels	0	0	0	0	0	0	0	0	0	1	2	3	1	6	4	5	4	3	1	0	30	6.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[5.2]	[8.8]	[3.3]	[24.0]	[18.7]	[27.8]	[31.1]	[30.6]	[17.6]	[0.0]	[4.7]	(3.9; 8.2)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	0	0	0	0	1	0	0	3	9	9	28	45	25	43	28	29	16	6	242	6.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.0]	[1.4]	[4.0]	[3.8]	[12.3]	[22.3]	[14.2]	[28.6]	[25.6]	[34.0]	[36.4]	[49.0]	[7.1]	(5.2; 6.8)
Wallonia	0	0	0	0	0	1	0	1	1	2	8	15	21	23	25	23	13	9	5	1	148	7.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.8]	[0.8]	[1.7]	[6.4]	[11.9]	[17.1]	[20.6]	[25.0]	[29.7]	[25.0]	[23.3]	[23.6]	[15.4]	[7.9]	(6.1; 8.5)

1.2. Oesophageal cancer incidence: by tumour stage

1.2.1. *Oesophageal cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023*

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	17 [0.5]	67 [7.0]	38 [8.5]	122 [2.1]	2.3 (1.9; 2.7)	10 [0.3]	18 [1.8]	17 [2.6]	45 [0.8]	0.7 (0.5; 0.9)
II	17 [0.5]	68 [7.1]	56 [12.6]	141 [2.4]	2.6 (2.2; 3.0)	6 [0.2]	38 [3.7]	42 [6.5]	86 [1.4]	1.3 (1.0; 1.6)
III	67 [2.0]	159 [16.6]	106 [23.8]	332 [5.8]	6.1 (5.4; 6.7)	10 [0.3]	43 [4.2]	34 [5.3]	87 [1.5]	1.3 (1.1; 1.6)
IV	86 [2.6]	222 [23.1]	120 [26.9]	428 [7.4]	7.7 (7.0; 8.5)	18 [0.5]	47 [4.6]	53 [8.2]	118 [2.0]	1.8 (1.5; 2.1)
X/NA	33 [1.0]	80 [8.3]	75 [16.8]	188 [3.3]	3.5 (3.0; 4.0)	12 [0.4]	32 [3.1]	40 [6.2]	84 [1.4]	1.3 (1.0; 1.6)

1.2.2. *Oesophageal cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023*

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	38 [1.1]	95 [9.9]	45 [10.1]	178 [3.1]	3.2 (2.7; 3.7)	11 [0.3]	25 [2.5]	15 [2.3]	51 [0.9]	0.8 (0.6; 1.1)
II	21 [0.6]	51 [5.3]	19 [4.3]	91 [1.6]	1.6 (1.3; 2.0)	5 [0.2]	12 [1.2]	5 [0.8]	22 [0.4]	0.4 (0.2; 0.5)
III	18 [0.5]	41 [4.3]	23 [5.2]	82 [1.4]	1.5 (1.2; 1.8)	2 [0.1]	12 [1.2]	3 [0.5]	17 [0.3]	0.3 (0.1; 0.4)
IV	19 [0.6]	42 [4.4]	18 [4.0]	79 [1.4]	1.4 (1.1; 1.7)	5 [0.2]	8 [0.8]	6 [0.9]	19 [0.3]	0.3 (0.2; 0.4)
X/NA	124 [3.7]	367 [38.3]	290 [65.1]	781 [13.6]	14.4 (13.4; 15.4)	33 [1.0]	121 [11.9]	157 [24.3]	311 [5.2]	4.7 (4.2; 5.2)

1.2.3. Oesophageal cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	33 [1.0]	95 [9.9]	54 [12.1]	182 [3.2]	3.3 (2.9; 3.8)	12 [0.4]	27 [2.7]	23 [3.6]	62 [1.0]	1.0 (0.7; 1.2)
II	18 [0.5]	59 [6.2]	48 [10.8]	125 [2.2]	2.3 (1.9; 2.7)	7 [0.2]	33 [3.2]	39 [6.0]	79 [1.3]	1.2 (0.9; 1.5)
III	65 [1.9]	159 [16.6]	111 [24.9]	335 [5.8]	6.1 (5.5; 6.8)	9 [0.3]	45 [4.4]	34 [5.3]	88 [1.5]	1.4 (1.1; 1.6)
IV	87 [2.6]	227 [23.7]	121 [27.2]	435 [7.6]	7.9 (7.1; 8.6)	18 [0.5]	49 [4.8]	54 [8.4]	121 [2.0]	1.8 (1.5; 2.2)
X/NA	17 [0.5]	56 [5.8]	61 [13.7]	134 [2.3]	2.5 (2.1; 2.9)	10 [0.3]	24 [2.4]	36 [5.6]	70 [1.2]	1.1 (0.8; 1.3)

1.3. Oesophageal cancer incidence: by tumour type

1.3.1. *Oesophageal cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023*

Type	Males					Females				
	N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
ADC	163 [4.8]	390 [40.7]	282 [63.3]	835 [14.5]	15.3 (14.2; 16.3)	24 [0.7]	64 [6.3]	88 [13.6]	176 [3.0]	2.7 (2.3; 3.0)
SCC	47 [1.4]	175 [18.2]	85 [19.1]	307 [5.3]	5.5 (4.9; 6.2)	24 [0.7]	104 [10.2]	84 [13.0]	212 [3.6]	3.3 (2.8; 3.7)
Other and unspecified	10 [0.3]	31 [3.2]	28 [6.3]	69 [1.2]	1.3 (1.0; 1.6)	8 [0.2]	10 [1.0]	14 [2.2]	32 [0.5]	0.5 (0.3; 0.7)

1.4. Oesophageal cancer incidence: by tumour sub-location

1.4.1. *Oesophageal cancer incidence by sub-location, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023*

Sub-location	Males					Females				
	N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
Cervical	25 [0.7]	39 [4.1]	23 [5.2]	87 [1.5]	1.6 (1.2; 1.9)	6 [0.2]	27 [2.7]	26 [4.0]	59 [1.0]	0.9 (0.7; 1.2)
Thoracic	17 [0.5]	65 [6.8]	38 [8.5]	120 [2.1]	2.2 (1.8; 2.6)	14 [0.4]	52 [5.1]	43 [6.7]	109 [1.8]	1.7 (1.4; 2.0)
Abdominal	170 [5.0]	459 [47.9]	314 [70.5]	943 [16.4]	17.2 (16.1; 18.3)	32 [1.0]	87 [8.6]	104 [16.1]	223 [3.8]	3.4 (3.0; 3.9)
Unspecified	8 [0.2]	33 [3.4]	20 [4.5]	61 [1.1]	1.1 (0.8; 1.4)	4 [0.1]	12 [1.2]	13 [2.0]	29 [0.5]	0.4 (0.3; 0.6)

Note: The sub-location 'Abdominal' includes cardia (C16.0).

1.5. Oesophageal cancer incidence: by tumour type and tumour stage

1.5.1. *Oesophageal cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023*

Type	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
ADC	I	27 [0.8]	71 [7.4]	46 [10.3]	144 [2.5]	2.7 (2.2; 3.1)	5 [0.2]	11 [1.1]	12 [1.9]	28 [0.5]	0.4 (0.3; 0.6)
	II	9 [0.3]	23 [2.4]	32 [7.2]	64 [1.1]	1.2 (0.9; 1.5)	3 [0.1]	9 [0.9]	10 [1.5]	22 [0.4]	0.3 (0.2; 0.5)
	III	50 [1.5]	105 [10.9]	87 [19.5]	242 [4.2]	4.4 (3.9; 5.0)	4 [0.1]	17 [1.7]	21 [3.3]	42 [0.7]	0.6 (0.4; 0.8)
	IV	73 [2.2]	174 [18.1]	98 [22.0]	345 [6.0]	6.2 (5.6; 6.9)	9 [0.3]	25 [2.5]	41 [6.4]	75 [1.3]	1.1 (0.9; 1.4)
	X/NA	4 [0.1]	17 [1.8]	19 [4.3]	40 [0.7]	0.7 (0.5; 1.0)	3 [0.1]	2 [0.2]	4 [0.6]	9 [0.2]	0.1 (0.0; 0.2)
SCC	I	6 [0.2]	24 [2.5]	6 [1.3]	36 [0.6]	0.6 (0.4; 0.9)	7 [0.2]	16 [1.6]	10 [1.5]	33 [0.6]	0.5 (0.4; 0.7)
	II	9 [0.3]	36 [3.8]	16 [3.6]	61 [1.1]	1.1 (0.8; 1.4)	4 [0.1]	24 [2.4]	29 [4.5]	57 [1.0]	0.9 (0.6; 1.1)
	III	15 [0.4]	54 [5.6]	24 [5.4]	93 [1.6]	1.7 (1.3; 2.0)	5 [0.2]	28 [2.8]	13 [2.0]	46 [0.8]	0.7 (0.5; 0.9)
	IV	14 [0.4]	53 [5.5]	23 [5.2]	90 [1.6]	1.6 (1.3; 1.9)	8 [0.2]	24 [2.4]	13 [2.0]	45 [0.8]	0.7 (0.5; 0.9)
	X/NA	3 [0.1]	8 [0.8]	16 [3.6]	27 [0.5]	0.5 (0.3; 0.7)	0 [0.0]	12 [1.2]	19 [2.9]	31 [0.5]	0.5 (0.3; 0.6)
Other and unspecified	I	0 [0.0]	0 [0.0]	2 [0.4]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
	II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)
	X/NA	10 [0.3]	31 [3.2]	26 [5.8]	67 [1.2]	1.2 (0.9; 1.5)	7 [0.2]	10 [1.0]	13 [2.0]	30 [0.5]	0.5 (0.3; 0.7)

1.6. Oesophageal cancer incidence: by tumour sub-location and tumour stage

1.6.1. *Oesophageal cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023*

Sub-location	Stage	Males					Females				
		N[CR]	ESR2013 (95%CI)				N[CR]	ESR2013 (95%CI)			
			15-59	60-74	75+	All ages		15-59	60-74	75+	All ages
Cervical	I	0 [0.0]	7 [0.7]	0 [0.0]	7 [0.1]	0.1 (0.0; 0.2)	2 [0.1]	6 [0.6]	2 [0.3]	10 [0.2]	0.2 (0.1; 0.3)
	II	3 [0.1]	5 [0.5]	7 [1.6]	15 [0.3]	0.3 (0.1; 0.4)	0 [0.0]	7 [0.7]	8 [1.2]	15 [0.3]	0.2 (0.1; 0.4)
	III	8 [0.2]	12 [1.3]	5 [1.1]	25 [0.4]	0.4 (0.3; 0.6)	1 [0.0]	5 [0.5]	4 [0.6]	10 [0.2]	0.2 (0.1; 0.2)
	IV	12 [0.4]	10 [1.0]	5 [1.1]	27 [0.5]	0.5 (0.3; 0.7)	2 [0.1]	4 [0.4]	5 [0.8]	11 [0.2]	0.2 (0.1; 0.3)
	X/NA	2 [0.1]	5 [0.5]	6 [1.3]	13 [0.2]	0.2 (0.1; 0.4)	1 [0.0]	5 [0.5]	7 [1.1]	13 [0.2]	0.2 (0.1; 0.3)
Thoracic	I	3 [0.1]	9 [0.9]	5 [1.1]	17 [0.3]	0.3 (0.2; 0.5)	3 [0.1]	8 [0.8]	2 [0.3]	13 [0.2]	0.2 (0.1; 0.3)
	II	3 [0.1]	13 [1.4]	2 [0.4]	18 [0.3]	0.3 (0.2; 0.5)	2 [0.1]	13 [1.3]	13 [2.0]	28 [0.5]	0.4 (0.3; 0.6)
	III	6 [0.2]	18 [1.9]	11 [2.5]	35 [0.6]	0.6 (0.4; 0.8)	3 [0.1]	17 [1.7]	8 [1.2]	28 [0.5]	0.4 (0.3; 0.6)
	IV	5 [0.1]	18 [1.9]	12 [2.7]	35 [0.6]	0.6 (0.4; 0.8)	6 [0.2]	10 [1.0]	10 [1.5]	26 [0.4]	0.4 (0.2; 0.6)
	X/NA	0 [0.0]	7 [0.7]	8 [1.8]	15 [0.3]	0.3 (0.1; 0.4)	0 [0.0]	4 [0.4]	10 [1.5]	14 [0.2]	0.2 (0.1; 0.3)
Abdominal	I	28 [0.8]	74 [7.7]	47 [10.6]	149 [2.6]	2.7 (2.3; 3.2)	6 [0.2]	13 [1.3]	15 [2.3]	34 [0.6]	0.5 (0.4; 0.7)
	II	11 [0.3]	32 [3.3]	36 [8.1]	79 [1.4]	1.5 (1.1; 1.8)	4 [0.1]	12 [1.2]	16 [2.5]	32 [0.5]	0.5 (0.3; 0.7)
	III	48 [1.4]	124 [12.9]	90 [20.2]	262 [4.5]	4.8 (4.2; 5.4)	4 [0.1]	21 [2.1]	20 [3.1]	45 [0.8]	0.7 (0.5; 0.9)
	IV	69 [2.0]	188 [19.6]	99 [22.2]	356 [6.2]	6.4 (5.8; 7.1)	10 [0.3]	32 [3.1]	36 [5.6]	78 [1.3]	1.2 (0.9; 1.5)
	X/NA	14 [0.4]	41 [4.3]	42 [9.4]	97 [1.7]	1.8 (1.4; 2.2)	8 [0.2]	9 [0.9]	17 [2.6]	34 [0.6]	0.5 (0.3; 0.7)
Unspecified	I	2 [0.1]	5 [0.5]	2 [0.4]	9 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	0 [0.0]	4 [0.6]	5 [0.1]	0.1 (0.0; 0.1)
	II	1 [0.0]	9 [0.9]	3 [0.7]	13 [0.2]	0.2 (0.1; 0.4)	1 [0.0]	1 [0.1]	2 [0.3]	4 [0.1]	0.1 (0.0; 0.1)
	III	3 [0.1]	5 [0.5]	5 [1.1]	13 [0.2]	0.2 (0.1; 0.4)	1 [0.0]	2 [0.2]	2 [0.3]	5 [0.1]	0.1 (0.0; 0.1)
	IV	1 [0.0]	11 [1.1]	5 [1.1]	17 [0.3]	0.3 (0.2; 0.5)	0 [0.0]	3 [0.3]	3 [0.5]	6 [0.1]	0.1 (0.0; 0.2)

Sub-location	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
X/NA		1 [0.0]	3 [0.3]	5 [1.1]	9 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	6 [0.6]	2 [0.3]	9 [0.2]	0.1 (0.0; 0.2)

Note: The sub-location 'Abdominal' includes cardia (C16.0).

1.7. Oesophageal cancer incidence: by tumour sub-location and tumour type

1.7.1. *Oesophageal cancer incidence by sub-location, type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023*

Sub-location	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
Cervical	ADC	6 [0.2]	2 [0.2]	2 [0.4]	10 [0.2]	0.2 (0.1; 0.3)	0 [0.0]	1 [0.1]	4 [0.6]	5 [0.1]	0.1 (0.0; 0.1)
	SCC	18 [0.5]	35 [3.6]	20 [4.5]	73 [1.3]	1.3 (1.0; 1.6)	5 [0.2]	25 [2.5]	20 [3.1]	50 [0.8]	0.8 (0.6; 1.0)
	Other and unspecified	1 [0.0]	2 [0.2]	1 [0.2]	4 [0.1]	0.1 (0.0; 0.1)	1 [0.0]	1 [0.1]	2 [0.3]	4 [0.1]	0.1 (0.0; 0.1)
Thoracic	ADC	1 [0.0]	4 [0.4]	11 [2.5]	16 [0.3]	0.3 (0.2; 0.5)	0 [0.0]	2 [0.2]	6 [0.9]	8 [0.1]	0.1 (0.0; 0.2)
	SCC	16 [0.5]	57 [5.9]	25 [5.6]	98 [1.7]	1.8 (1.4; 2.1)	14 [0.4]	47 [4.6]	35 [5.4]	96 [1.6]	1.5 (1.2; 1.8)
	Other and unspecified	0 [0.0]	4 [0.4]	2 [0.4]	6 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	3 [0.3]	2 [0.3]	5 [0.1]	0.1 (0.0; 0.1)
Abdominal	ADC	154 [4.6]	379 [39.5]	262 [58.8]	795 [13.8]	14.5 (13.5; 15.5)	24 [0.7]	59 [5.8]	75 [11.6]	158 [2.7]	2.4 (2.0; 2.8)
	SCC	7 [0.2]	55 [5.7]	29 [6.5]	91 [1.6]	1.7 (1.3; 2.0)	2 [0.1]	22 [2.2]	19 [2.9]	43 [0.7]	0.6 (0.5; 0.8)
	Other and unspecified	9 [0.3]	25 [2.6]	23 [5.2]	57 [1.0]	1.1 (0.8; 1.3)	6 [0.2]	6 [0.6]	10 [1.5]	22 [0.4]	0.4 (0.2; 0.5)
Unspecified	ADC	2 [0.1]	5 [0.5]	7 [1.6]	14 [0.2]	0.3 (0.1; 0.4)	0 [0.0]	2 [0.2]	3 [0.5]	5 [0.1]	0.1 (0.0; 0.1)
	SCC	6 [0.2]	28 [2.9]	11 [2.5]	45 [0.8]	0.8 (0.6; 1.0)	3 [0.1]	10 [1.0]	10 [1.5]	23 [0.4]	0.4 (0.2; 0.5)
	Other and unspecified	0 [0.0]	0 [0.0]	2 [0.4]	2 [0.0]	0.0 (0.0; 0.1)	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)

Note: The sub-location 'Abdominal' includes cardia (C16.0).

2. CANCER INCIDENCE TRENDS



2.1. Oesophageal cancer incidence trends: by region

2.1.1. Oesophageal cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium N	850	894	937	975	916	990	987	1,088	1,051	1,072	1,070	1,099	1,117	1,162	1,236	1,216	1,174	1,205	1,149	1,211		
CR	16.7	17.5	18.2	18.8	17.5	18.8	18.6	20.3	19.4	19.7	19.5	20.0	20.2	20.9	22.1	21.6	20.7	21.2	20.1	21.0		
ESR2013	20.5	21.1	22.1	22.2	20.8	22.3	21.9	23.9	22.3	22.6	22.3	22.4	22.4	23.3	24.2	23.4	22.4	22.9	21.3	22.1	0.1 (-0.2; 0.4)	2004-2023
																					0.7 (0.1; 1.3)	2004-2014
																					1.0 (-0.4; 2.4)	2015-2018
																					-1.7 (-3.1; -0.3)	2019-2023
Brussels N	65	57	67	70	62	77	65	74	79	78	87	58	60	85	67	69	67	67	67	62		
CR	13.5	11.8	13.7	14.1	12.3	14.9	12.3	13.6	14.3	13.9	15.4	10.1	10.3	14.6	11.4	11.6	11.2	11.2	11.2	10.2		
ESR2013	20.5	17.0	19.6	19.9	18.1	22.8	18.7	22.1	21.0	22.4	24.5	16.0	16.8	23.1	17.8	18.2	17.1	18.1	17.3	16.2	-0.8 (-1.8; 0.3)	2004-2023
Flanders N	498	521	555	597	553	605	595	613	618	651	659	667	708	681	763	745	757	768	727	714		
CR	16.8	17.5	18.5	19.8	18.2	19.7	19.3	19.7	19.7	20.7	20.8	21.0	22.1	21.1	23.5	22.9	23.1	23.3	21.9	21.3		
ESR2013	19.8	20.5	21.6	22.3	20.6	22.5	21.6	21.9	21.6	22.5	22.3	22.0	22.9	22.2	24.3	23.3	23.3	23.4	21.7	21.0	0.4 (0.1; 0.8)	2004-2023
																					1.0 (0.4; 1.6)	2004-2015
																					-0.3 (-1.2; 0.5)	2016-2023
Wallonia N	287	316	315	308	301	308	327	401	354	343	324	374	349	396	406	402	350	370	355	435		

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
CR	17.5	19.2	19.0	18.5	17.9	18.2	19.2	23.4	20.5	19.8	18.6	21.4	19.9	22.4	22.9	22.6	19.6	20.7	19.8	24.2		
ESR2013	21.5	23.2	24.0	22.5	21.9	21.5	22.9	28.4	24.0	22.9	21.5	24.5	22.7	25.5	25.4	25.0	21.9	22.7	21.5	25.7	0.3 (-0.4; 0.9)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Oesophageal cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	N	293	310	277	312	292	305	324	348	359	372	388	377	396	369	405	392	390	391	435	420		
	CR	5.5	5.8	5.2	5.8	5.4	5.6	5.9	6.2	6.4	6.6	6.8	6.6	6.9	6.4	7.0	6.8	6.7	6.7	7.4	7.1		
	ESR2013	5.6	5.9	5.2	5.8	5.4	5.5	5.8	6.1	6.2	6.4	6.6	6.3	6.6	6.1	6.6	6.4	6.2	6.2	6.8	6.4	0.9 (0.5; 1.3)	2004-2023
																						1.4 (0.8; 2.1)	2004-2016
																							0.0 (-1.2; 1.1)
Brussels	N	30	27	20	36	39	24	29	30	34	30	25	27	32	29	30	22	28	17	35	30		
	CR	5.8	5.2	3.8	6.7	7.2	4.3	5.2	5.2	5.8	5.1	4.2	4.5	5.3	4.8	4.9	3.6	4.5	2.7	5.6	4.7		
	ESR2013	7.0	5.9	4.3	7.6	7.8	4.4	6.2	5.8	6.5	6.0	5.5	5.5	6.7	5.6	5.9	4.3	5.8	3.5	7.1	6.0	-0.8 (-2.4; 0.9)	2004-2023
Flanders	N	156	178	166	166	149	182	174	215	198	210	213	225	225	208	239	234	235	248	242	242		
	CR	5.1	5.8	5.4	5.4	4.8	5.8	5.5	6.7	6.2	6.5	6.6	6.9	6.9	6.3	7.2	7.0	7.0	7.4	7.2	7.1		
	ESR2013	5.1	5.8	5.3	5.2	4.6	5.6	5.2	6.4	5.7	6.1	6.0	6.3	6.2	5.7	6.5	6.3	6.2	6.5	6.2	6.0	1.1 (0.6; 1.7)	2004-2023
Wallonia	N	107	105	91	110	104	99	121	103	127	132	150	125	139	132	136	136	127	126	158	148		
	CR	6.1	6.0	5.2	6.2	5.8	5.5	6.7	5.7	7.0	7.2	8.2	6.8	7.5	7.1	7.3	7.3	6.8	6.8	8.4	7.9		
	ESR2013	6.3	6.1	5.3	6.3	6.1	5.6	6.9	5.6	7.0	7.2	7.9	6.5	7.2	7.0	7.0	6.9	6.4	6.3	7.8	7.3	1.1 (0.4; 1.8)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Oesophageal cancer incidence trends: by tumour stage

2.2.1. Oesophageal cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Stage	Males							Females						
	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
I	N	163	155	156	176	182		46	53	45	63	62		
	CR	2.9	2.7	2.7	3.1	3.2		0.8	0.9	0.8	1.1	1.0		
	ESR2013	3.1	2.9	3.0	3.3	3.3	1.4 (0.8; 2.0) 2004-2023	0.8	0.9	0.7	1.0	1.0	2.5 (0.6; 4.4) 2004-2023	
							5.9 (3.9; 7.8) 2004-2011						6.4 (2.7; 10.1) 2004-2015	
							-1.1 (-2.1; -0.1) 2012-2023						-2.6 (-7.4; 2.4) 2016-2023	
II	N	137	119	111	102	125		72	74	52	66	79		
	CR	2.4	2.1	2.0	1.8	2.2		1.2	1.3	0.9	1.1	1.3		
	ESR2013	2.7	2.2	2.1	1.9	2.3	-2.9 (-3.6; -2.3) 2004-2023	1.1	1.2	0.8	1.1	1.2	0.4 (-0.9; 1.7) 2004-2023	
							-0.9 (-2.4; 0.5) 2004-2014							
							-5.1 (-6.6; -3.5) 2015-2023							
III	N	298	310	330	310	335		94	97	112	96	88		
	CR	5.3	5.5	5.8	5.4	5.8		1.6	1.7	1.9	1.6	1.5		
	ESR2013	5.7	5.9	6.2	5.8	6.1	2.3 (1.4; 3.1) 2004-2023	1.6	1.6	1.8	1.5	1.4	2.0 (1.0; 2.9) 2004-2023	
							6.8 (4.7; 8.9) 2004-2013						5.1 (3.0; 7.2) 2004-2014	
							-1.6 (-3.3; 0.1) 2014-2023						-1.4 (-3.6; 0.9) 2015-2023	
IV	N	488	455	479	448	435		124	108	112	136	121		
	CR	8.7	8.0	8.4	7.8	7.6		2.1	1.9	1.9	2.3	2.0		
	ESR2013	9.3	8.7	9.1	8.3	7.9	2.7 (1.7; 3.8) 2004-2023	2.1	1.7	1.8	2.1	1.8	3.5 (2.3; 4.7) 2004-2023	
							-0.2 (-2.3; 2.0) 2004-2013						2.3 (0.4; 4.2) 2004-2015	
							12.2 (7.3; 17.4) 2014-2017						12.5 (6.9; 18.5) 2016-2019	

Stage	Males							Females						
	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
						1.1 (-2.5; 4.9)	2018-2023						-1.6 (-7.8; 5.1)	2020-2023
X/NA N	130	135	129	113	134			56	58	70	74	70		
CR	2.3	2.4	2.3	2.0	2.3			1.0	1.0	1.2	1.3	1.2		
ESR2013	2.6	2.6	2.5	2.1	2.5	-5.3 (-6.2; -4.5)	2004-2023	0.8	0.8	1.1	1.1	1.1	-3.8 (-4.8; -2.8)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Oesophageal cancer incidence trends: by tumour type

2.3.1. Oesophageal cancer incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Type		Males							Females						
		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
ADC	N	866	789	810	782	835			158	188	165	184	176		
	CR	15.4	13.9	14.3	13.7	14.5			2.7	3.2	2.8	3.1	3.0		
	ESR2013	16.8	15.2	15.4	14.6	15.3	1.2 (0.7; 1.7)	2004-2023	2.5	3.0	2.5	2.8	2.7	0.7 (0.0; 1.4)	2004-2023
							2.4 (-0.5; 5.3)	2004-2008						1.9 (0.7; 3.0)	2004-2016
							1.9 (-0.3; 4.2)	2009-2012						-1.2 (-3.2; 0.9)	2017-2023
SCC	N	311	332	340	304	307			209	179	200	212	212		
	CR	5.5	5.9	6.0	5.3	5.3			3.6	3.1	3.4	3.6	3.6		
	ESR2013	5.9	6.2	6.4	5.6	5.5	-1.3 (-1.9; -0.8)	2004-2023	3.5	2.9	3.3	3.4	3.3	0.9 (0.4; 1.3)	2004-2023
Other and unspecified	N	39	53	55	63	69			25	23	26	39	32		
	CR	0.7	0.9	1.0	1.1	1.2			0.4	0.4	0.4	0.7	0.5		
	ESR2013	0.8	1.0	1.0	1.2	1.3	1.1 (0.0; 2.3)	2004-2023	0.4	0.3	0.4	0.6	0.5	0.2 (-1.4; 2.0)	2004-2023
														-16.9 (-24.6; -8.6)	2004-2008
														11.4 (3.3; 20.1)	2009-2012
														3.3 (0.6; 6.1)	2013-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Oesophageal cancer incidence trends: by tumour sub-location

2.4.1. Oesophageal cancer incidence trends by sub-location and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Sub-location		Males							Females						
		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Cervical	N	87	85	93	82	87			55	54	64	70	59		
	CR	1.5	1.5	1.6	1.4	1.5			0.9	0.9	1.1	1.2	1.0		
	ESR2013	1.7	1.6	1.7	1.5	1.6	3.1 (2.0; 4.2)	2004-2023	0.9	0.9	1.0	1.1	0.9	7.3 (5.8; 8.8)	2004-2023
							6.2 (3.8; 8.6)	2004-2014							
Thoracic	N	122	146	139	128	120			90	70	86	92	109		
	CR	2.2	2.6	2.4	2.2	2.1			1.6	1.2	1.5	1.6	1.8		
	ESR2013	2.3	2.7	2.6	2.3	2.2	3.6 (2.6; 4.5)	2004-2023	1.5	1.1	1.4	1.4	1.7	5.1 (4.0; 6.2)	2004-2023
							7.2 (4.9; 9.6)	2004-2013							
Abdominal	N	903	851	899	866	943			209	229	206	228	223		
	CR	16.0	15.0	15.8	15.2	16.4			3.6	3.9	3.5	3.9	3.8		
	ESR2013	17.4	16.4	17.1	16.1	17.2	3.0 (2.6; 3.3)	2004-2023	3.4	3.6	3.3	3.5	3.4	3.2 (2.5; 3.8)	2004-2023
							4.2 (3.4; 4.9)	2004-2015						5.0 (3.8; 6.2)	2004-2015
Unspecified	N	104	92	74	73	61			38	37	35	45	29		
	CR	1.8	1.6	1.3	1.3	1.1			0.7	0.6	0.6	0.8	0.5		
	ESR2013	2.0	1.8	1.4	1.4	1.1	-9.8 (-10.8; -8.9)	2004-2023	0.6	0.6	0.5	0.7	0.4	-8.8 (-10.1; -7.5)	2004-2023
							-2.6 (-7.0; 2.1)	2004-2009						-5.4 (-8.8; -1.9)	2004-2012
							-11.9 (-16.0; -7.7)	2010-2013						-12.7 (-18.2; -6.8)	2013-2016

Sub-location	Males							Females						
	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
						-12.4 (-14.1; -10.7)	2014-2023						-10.2 (-14.0; -6.3)	2017-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Note: The sub-location 'Abdominal' includes cardia (C16.0).

2.5. Oesophageal cancer incidence trends: by age group

2.5.1. Oesophageal cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-59 N	295	296	293	327	277	289	282	307	294	279	260	261	260	240	252	240	224	214	193	220		
CR	9.2	9.2	9.1	10.1	8.5	8.8	8.6	9.3	8.9	8.4	7.8	7.8	7.8	7.2	7.6	7.2	6.7	6.4	5.8	6.5		
ESR2013	9.9	9.7	9.5	10.5	8.8	9.1	8.8	9.5	9.0	8.4	7.8	7.7	7.6	7.0	7.4	7.0	6.5	6.2	5.6	6.4	-2.7 (-3.1; -2.3)	2004-2023
																					-1.2 (-2.6; 0.4)	2004-2010
																					-3.4 (-4.0; -2.7)	2011-2023
60-74 N	365	393	407	396	413	442	435	462	504	497	478	537	540	579	641	616	590	596	579	596		
CR	53.6	57.4	59.2	56.6	58.0	60.8	58.7	61.1	65.5	63.4	60.0	66.1	64.9	67.6	72.9	68.6	64.3	63.8	61.2	62.1		
ESR2013	53.5	57.1	59.2	56.9	58.7	61.1	59.7	62.5	65.9	64.8	60.5	66.9	65.5	68.7	74.0	69.3	65.2	64.6	62.2	63.3	0.9 (0.5; 1.3)	2004-2023
																					1.9 (1.2; 2.8)	2004-2014
																					-0.2 (-1.1; 0.7)	2015-2023
75+ N	190	205	237	252	226	259	270	319	253	296	332	301	317	343	343	360	360	395	377	395		
CR	64.8	67.7	75.5	77.4	67.1	74.9	76.3	88.3	68.5	78.7	86.6	76.9	80.3	86.9	86.3	89.1	87.1	94.9	87.4	88.7		
ESR2013	65.1	66.2	75.4	73.5	65.9	76.0	76.0	89.7	68.5	78.1	86.0	75.6	79.4	87.3	85.6	87.5	87.6	95.0	86.5	88.0	1.6 (1.0; 2.2)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.5.2. Oesophageal cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-59 N	59	68	66	75	61	69	67	85	83	71	56	65	73	65	64	62	51	63	64	56		
CR	1.9	2.2	2.1	2.4	1.9	2.1	2.1	2.6	2.5	2.2	1.7	2.0	2.2	2.0	1.9	1.9	1.6	1.9	1.9	1.7		
ESR2013	2.0	2.3	2.2	2.4	2.0	2.2	2.1	2.6	2.5	2.1	1.7	1.9	2.1	1.9	1.9	1.8	1.5	1.9	1.9	1.7	-1.5 (-2.4; -0.6)	2004-2023
60-74 N	113	117	104	104	114	107	121	111	125	155	162	158	164	161	180	148	184	165	186	178		
CR	14.6	15.1	13.5	13.3	14.5	13.4	14.9	13.5	15.0	18.3	18.9	18.1	18.4	17.5	19.1	15.4	18.8	16.6	18.5	17.5		
ESR2013	14.1	15.0	13.4	13.3	14.4	13.6	15.1	13.5	15.1	18.4	19.2	18.2	18.4	17.9	19.3	15.5	18.9	16.7	18.6	17.6	1.4 (0.5; 2.3)	2004-2023
																					2.1 (1.1; 3.0)	2004-2020
																					-2.3 (-8.2; 4.1)	2021-2023
75+ N	121	125	107	133	117	129	136	152	151	146	170	154	159	143	161	182	155	163	185	186		
CR	23.3	23.5	19.7	23.9	20.5	22.3	23.2	25.6	25.2	24.2	27.9	25.0	25.8	23.3	26.3	29.6	25.0	26.3	29.2	28.8		
ESR2013	23.8	23.7	19.2	23.8	20.3	22.3	23.3	25.5	24.2	23.7	27.2	24.4	25.2	22.9	26.1	30.7	24.8	26.6	28.9	28.6	1.4 (0.7; 2.0)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Oesophageal cancer prevalence: by region

3.1.1. *Oesophageal cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023*

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	N	953	2,585	3,575	4,138	4,436	302	904	1,263	1,502	1,612
	CR	16.4	44.6	61.7	71	77	5.1	15.2	21.2	25	27
	ESR2013	17.0	46.1	63.9	74.2	79.7	4.7	14.1	19.6	23.2	24.9
Brussels	N	49	132	188	226	242	22	60	78	96	105
	CR	8.0	21.6	30.7	36.9	39.5	3.5	9.4	12.2	15.1	16.5
	ESR2013	12.4	32.9	47.8	58.4	62.9	4.5	12.3	15.7	19.6	21.4
Flanders	N	571	1,604	2,212	2,547	2,737	169	531	752	896	964
	CR	16.9	47.5	65.5	75.4	81.0	4.9	15.4	21.8	26.0	28.0
	ESR2013	16.4	46.0	63.5	73.3	78.8	4.3	13.6	19.2	22.8	24.4
Wallonia	N	333	849	1,175	1,365	1,457	111	313	433	510	543
	CR	18.4	47.0	65.0	75.5	80.6	5.9	16.6	23.0	27.1	28.8
	ESR2013	19.3	49.2	68.3	79.7	85.3	5.5	15.4	21.1	24.8	26.4

4. CANCER SURVIVAL



4.1. Oesophageal cancer survival: by region

4.1.1. Oesophageal cancer survival by region, sex and age group: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	15,493	58.1% (57.3%; 58.9%)	33.9% (33.1%; 34.7%)	27.6% (26.8%; 28.5%)	21.2% (19.7%; 22.7%)
Males						
Belgium	All ages	11,557	59.2% (58.2%; 60.1%)	33.7% (32.7%; 34.6%)	27.2% (26.2%; 28.2%)	20.6% (19.0%; 22.3%)
	15-59	2,342	68.6% (66.8%; 70.6%)	41.4% (39.4%; 43.5%)	33.0% (31.0%; 35.1%)	25.6% (23.2%; 28.3%)
	60-74	5,710	63.1% (61.9%; 64.4%)	36.5% (35.2%; 37.9%)	29.8% (28.4%; 31.2%)	21.2% (19.2%; 23.5%)
	75+	3,505	46.4% (44.6%; 48.2%)	23.8% (22.1%; 25.6%)	19.1% (17.2%; 21.1%)	15.7% (12.4%; 20.0%)
Brussels	All ages	682	58.6% (54.9%; 62.6%)	34.4% (30.6%; 38.5%)	26.2% (22.4%; 30.7%)	16.6% (12.0%; 22.9%)
	15-59	161	69.2% (62.4%; 76.7%)	41.0% (33.8%; 49.7%)	28.8% (22.0%; 37.8%)	20.9% (13.7%; 32.0%)
	60-74	329	60.2% (55.0%; 65.9%)	33.5% (28.5%; 39.5%)	27.7% (22.6%; 34.0%)	17.0% (11.0%; 26.3%)
	75+	192	47.0% (40.0%; 55.3%)	30.2% (23.2%; 39.2%)	21.3% (14.3%; 31.8%)	FU<10y
Flanders	All ages	7,137	58.9% (57.7%; 60.1%)	33.5% (32.3%; 34.8%)	27.6% (26.4%; 29.0%)	21.3% (19.2%; 23.6%)
	15-59	1,370	69.2% (66.7%; 71.7%)	41.8% (39.2%; 44.6%)	33.0% (30.4%; 35.9%)	26.8% (23.8%; 30.3%)
	60-74	3,406	63.3% (61.7%; 65.0%)	37.3% (35.6%; 39.1%)	30.7% (28.9%; 32.6%)	21.4% (18.5%; 24.7%)
	75+	2,361	46.6% (44.5%; 48.8%)	23.3% (21.3%; 25.5%)	20.1% (17.8%; 22.6%)	16.8% (12.6%; 22.3%)
Wallonia	All ages	3,738	59.8% (58.2%; 61.4%)	33.7% (32.1%; 35.5%)	26.5% (24.8%; 28.3%)	20.4% (18.0%; 23.1%)

Net Survival Probability, 2014-2023						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	15-59	811	67.7% (64.5%; 71.0%)	40.8% (37.5%; 44.5%)	33.7% (30.3%; 37.4%)	25.1% (21.1%; 29.8%)
	60-74	1,975	63.3% (61.2%; 65.5%)	35.6% (33.4%; 38.0%)	28.5% (26.3%; 30.9%)	21.6% (18.8%; 24.9%)
	75+	952	45.7% (42.4%; 49.2%)	23.7% (20.6%; 27.3%)	16.0% (12.8%; 20.1%)	13.7% (8.8%; 21.5%)
Females						
Belgium	All ages	3,936	54.9% (53.3%; 56.6%)	34.6% (33.0%; 36.2%)	29.0% (27.3%; 30.7%)	22.8% (19.8%; 26.2%)
	15-59	613	73.0% (69.5%; 76.6%)	49.9% (46.0%; 54.1%)	40.7% (36.7%; 45.1%)	30.4% (25.7%; 35.9%)
	60-74	1,677	61.7% (59.4%; 64.1%)	39.5% (37.1%; 42.0%)	33.2% (30.7%; 35.8%)	27.2% (23.7%; 31.2%)
	75+	1,648	41.4% (38.9%; 44.0%)	23.9% (21.6%; 26.4%)	20.3% (17.8%; 23.2%)	15.7% (10.9%; 22.6%)
Brussels	All ages	274	52.9% (47.2%; 59.4%)	30.8% (25.4%; 37.5%)	26.5% (20.7%; 33.8%)	FU<10y
	15-59	59	71.4% (60.8%; 83.8%)	55.5% (44.0%; 70.1%)	42.1% (30.1%; 59.0%)	FU<10y
	60-74	112	52.3% (43.8%; 62.5%)	25.7% (18.3%; 36.1%)	21.7% (14.4%; 32.4%)	FU<10y
	75+	103	43.1% (34.2%; 54.4%)	22.5% (14.9%; 33.9%)	22.7% (14.2%; 36.4%)	FU<10y
Flanders	All ages	2,294	55.5% (53.4%; 57.7%)	35.6% (33.5%; 37.8%)	29.8% (27.6%; 32.2%)	24.2% (20.3%; 28.8%)
	15-59	343	76.3% (72.0%; 81.0%)	53.1% (48.0%; 58.7%)	44.6% (39.4%; 50.6%)	35.7% (29.5%; 43.3%)
	60-74	910	64.1% (61.0%; 67.4%)	42.7% (39.4%; 46.2%)	36.1% (32.7%; 39.8%)	31.6% (27.0%; 37.0%)
	75+	1,043	41.1% (38.1%; 44.4%)	23.7% (20.9%; 26.9%)	19.4% (16.3%; 23.0%)	14.6% (9.3%; 23.1%)
Wallonia	All ages	1,368	54.4% (51.7%; 57.2%)	33.5% (30.9%; 36.4%)	28.1% (25.3%; 31.1%)	21.7% (17.1%; 27.6%)
	15-59	211	68.0% (61.9%; 74.6%)	43.3% (36.9%; 50.7%)	33.6% (27.3%; 41.5%)	21.8% (15.4%; 30.9%)
	60-74	655	59.9% (56.2%; 63.8%)	37.3% (33.6%; 41.4%)	31.1% (27.3%; 35.3%)	23.1% (17.5%; 30.5%)
	75+	502	41.5% (37.2%; 46.3%)	24.5% (20.4%; 29.5%)	21.9% (17.4%; 27.6%)	19.4% (10.7%; 34.9%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2. Oesophageal cancer survival: by tumour stage

4.2.1. Oesophageal cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023							
cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	15,493	58.1% (57.3%; 58.9%)	41.6% (40.8%; 42.5%)	33.9% (33.1%; 34.7%)	29.9% (29.1%; 30.8%)	27.6% (26.8%; 28.5%)	21.2% (19.7%; 22.7%)
Males							
All	11,557	59.2% (58.2%; 60.1%)	41.8% (40.9%; 42.8%)	33.7% (32.7%; 34.6%)	29.5% (28.6%; 30.5%)	27.2% (26.2%; 28.2%)	20.6% (19.0%; 22.3%)
I	1,125	84.2% (81.9%; 86.6%)	74.5% (71.6%; 77.5%)	67.5% (64.3%; 70.9%)	61.8% (58.3%; 65.6%)	57.8% (54.0%; 61.9%)	47.0% (40.7%; 54.2%)
II	1,352	72.3% (69.8%; 74.9%)	53.8% (51.0%; 56.8%)	44.5% (41.5%; 47.6%)	39.7% (36.7%; 43.0%)	36.6% (33.5%; 40.0%)	25.3% (20.4%; 31.4%)
III	3,071	68.4% (66.7%; 70.1%)	48.2% (46.4%; 50.2%)	38.7% (36.8%; 40.7%)	33.8% (31.9%; 35.8%)	31.0% (29.1%; 33.0%)	20.9% (17.8%; 24.5%)
IV	3,913	41.4% (39.8%; 43.0%)	21.3% (20.0%; 22.7%)	13.3% (12.1%; 14.5%)	10.1% (9.0%; 11.3%)	8.9% (7.8%; 10.1%)	6.6% (4.5%; 9.7%)
X/NA	2,149	57.4% (55.3%; 59.7%)	46.0% (43.8%; 48.3%)	39.2% (36.9%; 41.6%)	35.4% (33.0%; 38.0%)	33.0% (30.5%; 35.6%)	27.8% (24.1%; 32.0%)
Females							
All	3,936	54.9% (53.3%; 56.6%)	41.1% (39.5%; 42.8%)	34.6% (33.0%; 36.2%)	31.0% (29.4%; 32.7%)	29.0% (27.3%; 30.7%)	22.8% (19.8%; 26.2%)
I	423	75.6% (71.5%; 80.1%)	69.4% (64.7%; 74.4%)	62.7% (57.6%; 68.3%)	56.7% (51.0%; 62.9%)	51.7% (45.6%; 58.5%)	44.0% (33.1%; 58.4%)
II	630	64.7% (60.9%; 68.7%)	50.0% (46.0%; 54.3%)	43.9% (39.9%; 48.5%)	37.0% (32.9%; 41.8%)	34.6% (30.4%; 39.5%)	29.0% (21.4%; 39.2%)
III	919	64.9% (61.7%; 68.2%)	47.1% (43.8%; 50.6%)	38.5% (35.3%; 42.1%)	35.4% (32.1%; 39.1%)	32.7% (29.2%; 36.6%)	23.2% (17.2%; 31.2%)
IV	1,023	35.6% (32.8%; 38.8%)	19.0% (16.7%; 21.7%)	13.1% (11.0%; 15.5%)	10.7% (8.8%; 13.1%)	10.0% (8.0%; 12.4%)	6.7% (4.6%; 9.7%)
X/NA	955	50.8% (47.6%; 54.2%)	41.0% (37.8%; 44.5%)	35.4% (32.1%; 38.9%)	33.4% (30.0%; 37.1%)	32.0% (28.6%; 35.9%)	26.3% (20.8%; 33.1%)

4.2.2. Oesophageal cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023							
pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	15,493	58.1% (57.3%; 58.9%)	41.6% (40.8%; 42.5%)	33.9% (33.1%; 34.7%)	29.9% (29.1%; 30.8%)	27.6% (26.8%; 28.5%)	21.2% (19.7%; 22.7%)
Males							
All	11,557	59.2% (58.2%; 60.1%)	41.8% (40.9%; 42.8%)	33.7% (32.7%; 34.6%)	29.5% (28.6%; 30.5%)	27.2% (26.2%; 28.2%)	20.6% (19.0%; 22.3%)
I	1,559	93.7% (92.3%; 95.2%)	88.2% (86.2%; 90.2%)	83.6% (81.3%; 86.1%)	80.1% (77.2%; 83.1%)	76.1% (72.8%; 79.5%)	65.0% (58.9%; 71.7%)
II	931	88.3% (86.0%; 90.6%)	74.7% (71.6%; 77.8%)	64.3% (60.8%; 67.9%)	58.8% (55.2%; 62.8%)	54.9% (51.0%; 59.2%)	37.9% (29.9%; 48.2%)
III	1,034	81.5% (79.1%; 84.1%)	59.0% (55.8%; 62.2%)	45.0% (41.8%; 48.5%)	37.7% (34.4%; 41.3%)	35.2% (31.9%; 38.9%)	26.0% (20.7%; 32.6%)
IV	740	50.4% (46.9%; 54.2%)	24.4% (21.4%; 27.9%)	13.5% (11.0%; 16.4%)	9.0% (7.0%; 11.8%)	6.8% (4.9%; 9.5%)	4.2% (2.2%; 8.0%)
X/NA	7,334	45.9% (44.8%; 47.1%)	27.3% (26.2%; 28.4%)	19.6% (18.6%; 20.7%)	16.0% (15.1%; 17.0%)	14.2% (13.2%; 15.2%)	9.6% (8.2%; 11.3%)
Females							
All	3,936	54.9% (53.3%; 56.6%)	41.1% (39.5%; 42.8%)	34.6% (33.0%; 36.2%)	31.0% (29.4%; 32.7%)	29.0% (27.3%; 30.7%)	22.8% (19.8%; 26.2%)
I	473	94.8% (92.5%; 97.2%)	91.2% (88.1%; 94.5%)	87.4% (83.6%; 91.4%)	84.7% (80.2%; 89.5%)	81.5% (76.3%; 87.1%)	81.0% (69.4%; 94.6%)
II	260	91.8% (88.3%; 95.5%)	79.3% (74.1%; 84.8%)	70.8% (64.9%; 77.3%)	62.6% (56.1%; 69.8%)	58.7% (51.8%; 66.4%)	46.6% (31.7%; 68.3%)
III	234	79.7% (74.4%; 85.3%)	62.6% (56.3%; 69.6%)	45.8% (39.3%; 53.4%)	41.1% (34.5%; 49.0%)	36.8% (30.0%; 45.3%)	21.2% (12.3%; 36.4%)
IV	184	50.7% (43.9%; 58.6%)	25.6% (19.9%; 32.9%)	14.1% (9.6%; 20.5%)	11.3% (7.3%; 17.6%)	8.2% (4.6%; 14.7%)	4.2% (1.6%; 11.2%)
X/NA	2,795	43.0% (41.2%; 45.0%)	28.4% (26.7%; 30.2%)	22.7% (21.1%; 24.5%)	19.5% (17.8%; 21.2%)	18.0% (16.3%; 19.8%)	11.6% (8.8%; 15.1%)

4.2.3. Oesophageal cancer survival by stage and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023							
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	15,493	58.1% (57.3%; 58.9%)	41.6% (40.8%; 42.5%)	33.9% (33.1%; 34.7%)	29.9% (29.1%; 30.8%)	27.6% (26.8%; 28.5%)	21.2% (19.7%; 22.7%)
Males							
All	11,557	59.2% (58.2%; 60.1%)	41.8% (40.9%; 42.8%)	33.7% (32.7%; 34.6%)	29.5% (28.6%; 30.5%)	27.2% (26.2%; 28.2%)	20.6% (19.0%; 22.3%)
I	1,634	88.4% (86.6%; 90.2%)	81.3% (79.1%; 83.6%)	75.3% (72.7%; 78.0%)	70.0% (67.0%; 73.1%)	66.1% (62.8%; 69.5%)	55.5% (49.9%; 61.8%)
II	1,301	72.1% (69.6%; 74.8%)	54.0% (51.1%; 57.1%)	44.3% (41.3%; 47.4%)	39.9% (36.8%; 43.1%)	36.7% (33.6%; 40.1%)	23.8% (18.9%; 30.1%)
III	3,206	69.1% (67.4%; 70.8%)	49.1% (47.3%; 51.0%)	39.2% (37.3%; 41.1%)	34.2% (32.4%; 36.2%)	31.4% (29.5%; 33.4%)	21.6% (18.7%; 24.9%)
IV	4,019	41.6% (40.1%; 43.2%)	21.2% (19.9%; 22.6%)	13.1% (12.0%; 14.4%)	9.9% (8.8%; 11.0%)	8.5% (7.5%; 9.7%)	6.4% (4.4%; 9.3%)
X/NA	1,452	42.0% (39.5%; 44.8%)	28.3% (25.9%; 30.9%)	22.1% (19.8%; 24.7%)	18.7% (16.5%; 21.3%)	16.9% (14.6%; 19.6%)	15.3% (11.9%; 19.7%)
Females							
All	3,936	54.9% (53.3%; 56.6%)	41.1% (39.5%; 42.8%)	34.6% (33.0%; 36.2%)	31.0% (29.4%; 32.7%)	29.0% (27.3%; 30.7%)	22.8% (19.8%; 26.2%)
I	583	81.9% (78.6%; 85.3%)	77.5% (73.8%; 81.4%)	72.0% (67.8%; 76.5%)	67.5% (62.8%; 72.6%)	63.3% (58.1%; 68.9%)	58.0% (47.4%; 71.0%)
II	619	65.2% (61.4%; 69.3%)	50.5% (46.5%; 54.9%)	44.3% (40.2%; 48.9%)	37.5% (33.3%; 42.2%)	34.8% (30.6%; 39.7%)	26.4% (19.5%; 35.8%)
III	953	65.2% (62.2%; 68.4%)	47.8% (44.6%; 51.3%)	38.7% (35.5%; 42.2%)	35.3% (32.0%; 38.9%)	32.7% (29.4%; 36.5%)	23.2% (17.4%; 30.8%)
IV	1,057	35.4% (32.6%; 38.4%)	18.7% (16.4%; 21.3%)	12.8% (10.8%; 15.2%)	10.2% (8.3%; 12.5%)	9.2% (7.3%; 11.5%)	6.5% (4.5%; 9.4%)
X/NA	739	40.3% (36.8%; 44.2%)	28.4% (25.1%; 32.1%)	23.1% (19.9%; 26.9%)	21.4% (18.1%; 25.3%)	20.4% (17.0%; 24.5%)	14.4% (10.0%; 20.6%)

4.3. Oesophageal cancer survival: by tumour type and tumour stage

4.3.1. Oesophageal cancer survival by type, stage and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023									
Type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Total		15,493	58.1% (57.3%; 58.9%)	41.6% (40.8%; 42.5%)	33.9% (33.1%; 34.7%)	29.9% (29.1%; 30.8%)	27.6% (26.8%; 28.5%)	21.2% (19.7%; 22.7%)	
Males									
Total	All	11,557	59.2% (58.2%; 60.1%)	41.8% (40.9%; 42.8%)	33.7% (32.7%; 34.6%)	29.5% (28.6%; 30.5%)	27.2% (26.2%; 28.2%)	20.6% (19.0%; 22.3%)	
	I	1,634	88.4% (86.6%; 90.2%)	81.3% (79.1%; 83.6%)	75.3% (72.7%; 78.0%)	70.0% (67.0%; 73.1%)	66.1% (62.8%; 69.5%)	55.5% (49.9%; 61.8%)	
	II	1,301	72.1% (69.6%; 74.8%)	54.0% (51.1%; 57.1%)	44.3% (41.3%; 47.4%)	39.9% (36.8%; 43.1%)	36.7% (33.6%; 40.1%)	23.8% (18.9%; 30.1%)	
	III	3,206	69.1% (67.4%; 70.8%)	49.1% (47.3%; 51.0%)	39.2% (37.3%; 41.1%)	34.2% (32.4%; 36.2%)	31.4% (29.5%; 33.4%)	21.6% (18.7%; 24.9%)	
	IV	4,019	41.6% (40.1%; 43.2%)	21.2% (19.9%; 22.6%)	13.1% (12.0%; 14.4%)	9.9% (8.8%; 11.0%)	8.5% (7.5%; 9.7%)	6.4% (4.4%; 9.3%)	
	X/NA	1,452	42.0% (39.5%; 44.8%)	28.3% (25.9%; 30.9%)	22.1% (19.8%; 24.7%)	18.7% (16.5%; 21.3%)	16.9% (14.6%; 19.6%)	15.3% (11.9%; 19.7%)	
ADC	All	7,807	62.0% (60.9%; 63.1%)	44.4% (43.3%; 45.6%)	35.7% (34.5%; 36.9%)	31.9% (30.7%; 33.1%)	29.9% (28.6%; 31.2%)	23.2% (21.1%; 25.5%)	
	I	1,217	90.9% (88.9%; 92.8%)	85.9% (83.4%; 88.4%)	81.3% (78.4%; 84.3%)	78.5% (75.1%; 82.1%)	75.0% (71.2%; 79.1%)	64.2% (57.0%; 72.3%)	
	II	678	76.7% (73.3%; 80.3%)	59.9% (55.9%; 64.2%)	48.6% (44.4%; 53.3%)	45.0% (40.6%; 49.8%)	43.2% (38.7%; 48.2%)	30.5% (22.9%; 40.4%)	
	III	2,227	72.0% (70.1%; 74.0%)	52.5% (50.3%; 54.8%)	41.6% (39.3%; 43.9%)	36.8% (34.6%; 39.3%)	34.7% (32.3%; 37.2%)	25.7% (22.0%; 30.2%)	
	IV	3,049	45.0% (43.2%; 46.9%)	23.3% (21.7%; 24.9%)	14.4% (13.1%; 15.8%)	10.6% (9.4%; 12.0%)	9.2% (8.0%; 10.6%)	6.4% (3.8%; 10.6%)	
	X/NA	638	37.6% (33.8%; 41.7%)	21.8% (18.5%; 25.5%)	15.1% (12.2%; 18.8%)	10.8% (8.2%; 14.2%)	8.7% (6.2%; 12.2%)	6.1% (3.8%; 10.0%)	
SCC	All	3,294	54.3% (52.6%; 56.1%)	36.8% (35.1%; 38.6%)	29.2% (27.5%; 30.9%)	24.1% (22.5%; 25.8%)	20.8% (19.2%; 22.5%)	13.9% (11.9%; 16.4%)	
	I	409	80.7% (76.8%; 84.9%)	67.7% (63.0%; 72.8%)	57.6% (52.5%; 63.2%)	44.7% (39.3%; 50.8%)	39.2% (33.7%; 45.5%)	30.8% (24.4%; 38.9%)	
	II	611	67.3% (63.5%; 71.2%)	47.6% (43.6%; 51.9%)	39.2% (35.1%; 43.7%)	33.7% (29.7%; 38.4%)	28.8% (24.7%; 33.5%)	13.9% (8.5%; 22.6%)	
	III	960	62.2% (59.1%; 65.5%)	41.3% (38.2%; 44.7%)	33.4% (30.3%; 36.8%)	28.1% (25.1%; 31.4%)	23.8% (20.8%; 27.2%)	13.5% (9.8%; 18.7%)	
	IV	913	31.9% (29.0%; 35.1%)	15.4% (13.2%; 18.1%)	9.5% (7.6%; 11.8%)	7.6% (5.9%; 9.9%)	6.5% (4.8%; 8.8%)	5.3% (3.4%; 8.1%)	
	X/NA	401	39.6% (35.0%; 44.8%)	26.9% (22.7%; 31.8%)	19.2% (15.5%; 23.9%)	15.7% (12.1%; 20.4%)	14.6% (11.0%; 19.4%)	14.0% (9.3%; 21.1%)	

Net Survival Probability, 2014-2023									
Type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Other and unspecified	All	513	49.2% (44.9%; 53.9%)	37.5% (33.2%; 42.2%)	33.9% (29.7%; 38.8%)	32.6% (28.2%; 37.8%)	31.2% (26.5%; 36.7%)	27.2% (19.2%; 38.5%)	
	I	9	N<50	N<50	N<50	N<50	N<50	N<50	
	II	12	N<50	N<50	N<50	N<50	N<50	N<50	
	III	21	N<50	N<50	N<50	N<50	N<50	N<50	
	IV	57	14.4% (7.8%; 26.8%)	3.8% (1.2%; 12.6%)	4.0% (1.2%; 13.2%)	4.4% (1.3%; 14.3%)	4.8% (1.5%; 15.7%)	FU<10y	
	X/NA	414	51.5% (46.7%; 56.7%)	40.2% (35.4%; 45.6%)	36.2% (31.3%; 41.8%)	35.1% (30.0%; 40.9%)	33.3% (27.9%; 39.7%)	33.1% (22.7%; 48.2%)	
Females									
Total	All	3,936	54.9% (53.3%; 56.6%)	41.1% (39.5%; 42.8%)	34.6% (33.0%; 36.2%)	31.0% (29.4%; 32.7%)	29.0% (27.3%; 30.7%)	22.8% (19.8%; 26.2%)	
	I	583	81.9% (78.6%; 85.3%)	77.5% (73.8%; 81.4%)	72.0% (67.8%; 76.5%)	67.5% (62.8%; 72.6%)	63.3% (58.1%; 68.9%)	58.0% (47.4%; 71.0%)	
	II	619	65.2% (61.4%; 69.3%)	50.5% (46.5%; 54.9%)	44.3% (40.2%; 48.9%)	37.5% (33.3%; 42.2%)	34.8% (30.6%; 39.7%)	26.4% (19.5%; 35.8%)	
	III	953	65.2% (62.2%; 68.4%)	47.8% (44.6%; 51.3%)	38.7% (35.5%; 42.2%)	35.3% (32.0%; 38.9%)	32.7% (29.4%; 36.5%)	23.2% (17.4%; 30.8%)	
	IV	1,057	35.4% (32.6%; 38.4%)	18.7% (16.4%; 21.3%)	12.8% (10.8%; 15.2%)	10.2% (8.3%; 12.5%)	9.2% (7.3%; 11.5%)	6.5% (4.5%; 9.4%)	
	X/NA	739	40.3% (36.8%; 44.2%)	28.4% (25.1%; 32.1%)	23.1% (19.9%; 26.9%)	21.4% (18.1%; 25.3%)	20.4% (17.0%; 24.5%)	14.4% (10.0%; 20.6%)	
ADC	All	1,753	56.6% (54.2%; 59.1%)	41.3% (38.9%; 43.8%)	33.6% (31.2%; 36.2%)	30.3% (27.9%; 33.0%)	28.3% (25.8%; 31.1%)	23.3% (18.8%; 28.8%)	
	I	259	90.7% (86.6%; 94.9%)	86.4% (81.4%; 91.7%)	82.5% (76.6%; 88.9%)	80.0% (73.1%; 87.5%)	77.2% (69.6%; 85.7%)	76.0% (58.6%; 98.6%)	
	II	177	68.9% (61.9%; 76.6%)	55.1% (47.6%; 63.8%)	46.7% (39.0%; 55.9%)	39.9% (32.0%; 49.7%)	39.2% (31.2%; 49.3%)	26.5% (16.4%; 42.8%)	
	III	488	69.0% (64.8%; 73.5%)	50.5% (45.9%; 55.6%)	39.4% (34.9%; 44.6%)	36.2% (31.6%; 41.5%)	32.3% (27.5%; 38.0%)	22.9% (14.6%; 36.0%)	
	IV	599	38.2% (34.4%; 42.4%)	19.5% (16.5%; 23.1%)	13.1% (10.5%; 16.4%)	9.6% (7.2%; 12.7%)	8.0% (5.6%; 11.2%)	4.7% (2.6%; 8.5%)	
	X/NA	230	30.4% (24.7%; 37.4%)	16.9% (12.3%; 23.3%)	9.5% (5.9%; 15.3%)	7.9% (4.5%; 13.7%)	7.7% (4.3%; 13.8%)	FU<10y	
SCC	All	1,931	53.5% (51.3%; 55.9%)	40.7% (38.4%; 43.0%)	34.7% (32.5%; 37.1%)	30.8% (28.5%; 33.1%)	28.3% (26.1%; 30.8%)	21.4% (17.8%; 25.8%)	
	I	313	74.9% (70.1%; 80.1%)	70.1% (64.9%; 75.8%)	63.0% (57.3%; 69.3%)	56.9% (50.7%; 63.7%)	51.4% (44.8%; 59.0%)	40.6% (29.3%; 56.4%)	
	II	436	63.9% (59.4%; 68.8%)	48.7% (44.0%; 53.9%)	43.5% (38.7%; 48.9%)	36.5% (31.6%; 42.1%)	32.9% (27.9%; 38.6%)	29.8% (22.9%; 38.7%)	
	III	457	61.2% (56.8%; 66.0%)	45.1% (40.6%; 50.1%)	37.9% (33.5%; 42.9%)	34.3% (29.8%; 39.4%)	33.0% (28.5%; 38.2%)	22.3% (16.1%; 30.9%)	
	IV	443	32.1% (28.0%; 36.8%)	18.3% (14.9%; 22.4%)	12.8% (9.9%; 16.6%)	11.3% (8.5%; 15.1%)	11.1% (8.2%; 14.9%)	9.4% (6.3%; 14.0%)	

Net Survival Probability, 2014-2023								
Type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	283	35.2% (30.0%; 41.4%)	23.8% (19.1%; 29.5%)	19.2% (14.9%; 24.8%)	17.9% (13.6%; 23.5%)	15.2% (11.2%; 20.8%)	FU<10y
Other and unspecified	All	269	55.3% (49.5%; 61.8%)	44.5% (38.5%; 51.3%)	41.3% (35.1%; 48.4%)	38.7% (31.9%; 46.8%)	39.0% (31.8%; 47.9%)	29.4% (19.9%; 43.4%)
	I	12	N<50	N<50	N<50	N<50	N<50	N<50
	II	6	N<50	N<50	N<50	N<50	N<50	N<50
	III	8	N<50	N<50	N<50	N<50	N<50	N<50
	IV	15	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	228	56.4% (50.1%; 63.4%)	45.6% (39.2%; 53.2%)	42.2% (35.5%; 50.2%)	40.0% (32.6%; 49.1%)	41.2% (33.1%; 51.3%)	25.8% (15.1%; 44.0%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

5. CANCER SURVIVAL TRENDS



5.1. Oesophageal cancer survival trends: by tumour stage

5.1.1. Oesophageal cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2023

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2008	All	4,539	54.0% (52.5%; 55.5%)	28.0% (26.6%; 29.4%)	22.4% (21.0%; 23.8%)	1,477	49.3% (46.8%; 52.0%)	27.3% (25.0%; 29.8%)	21.9% (19.7%; 24.4%)
	I	567	87.5% (84.5%; 90.6%)	74.2% (70.1%; 78.7%)	67.3% (62.6%; 72.5%)	170	85.5% (79.9%; 91.5%)	71.2% (63.9%; 79.5%)	68.1% (59.8%; 77.5%)
	II	737	68.7% (65.3%; 72.3%)	40.6% (37.0%; 44.7%)	33.0% (29.4%; 37.0%)	262	63.0% (57.2%; 69.5%)	35.1% (29.4%; 41.9%)	28.5% (23.0%; 35.3%)
	III	940	59.1% (55.9%; 62.4%)	25.1% (22.3%; 28.2%)	18.1% (15.6%; 20.9%)	291	56.7% (51.2%; 62.8%)	31.2% (26.1%; 37.2%)	21.9% (17.3%; 27.6%)
	IV	1,137	39.9% (37.1%; 42.9%)	8.8% (7.3%; 10.7%)	5.5% (4.3%; 7.2%)	269	36.2% (30.9%; 42.5%)	8.3% (5.6%; 12.5%)	4.1% (2.2%; 7.4%)
	X/NA	1,163	38.0% (35.3%; 41.0%)	18.3% (16.0%; 20.8%)	13.4% (11.3%; 15.9%)	486	32.1% (28.1%; 36.7%)	16.0% (12.8%; 19.9%)	12.3% (9.3%; 16.2%)
2009-2013	All	5,167	56.0% (54.6%; 57.4%)	29.6% (28.3%; 31.0%)	23.4% (22.1%; 24.7%)	1,697	54.8% (52.4%; 57.4%)	31.5% (29.2%; 34.0%)	27.0% (24.7%; 29.5%)
	I	795	85.3% (82.6%; 88.1%)	70.9% (67.3%; 74.8%)	64.5% (60.4%; 68.9%)	235	84.0% (78.9%; 89.3%)	69.8% (63.1%; 77.2%)	64.8% (57.3%; 73.3%)
	II	754	70.3% (66.9%; 73.8%)	40.1% (36.5%; 44.0%)	31.8% (28.3%; 35.8%)	301	63.2% (57.8%; 69.1%)	38.5% (33.1%; 44.9%)	33.2% (27.8%; 39.5%)
	III	1,443	62.5% (59.9%; 65.1%)	29.5% (27.1%; 32.1%)	21.9% (19.7%; 24.4%)	408	64.3% (59.7%; 69.3%)	33.7% (29.2%; 38.9%)	26.9% (22.7%; 32.0%)
	IV	1,222	35.9% (33.3%; 38.8%)	7.5% (6.1%; 9.2%)	3.7% (2.8%; 5.0%)	305	34.7% (29.7%; 40.6%)	10.0% (7.1%; 14.1%)	6.5% (4.2%; 10.1%)
	X/NA	964	36.7% (33.6%; 40.0%)	15.7% (13.4%; 18.4%)	10.3% (8.3%; 12.8%)	451	39.4% (35.0%; 44.5%)	19.8% (16.0%; 24.4%)	17.5% (13.7%; 22.4%)
2014-2018	All	5,654	57.1% (55.7%; 58.4%)	31.6% (30.3%; 32.9%)	25.6% (24.3%; 26.9%)	1,922	52.8% (50.6%; 55.2%)	31.8% (29.7%; 34.1%)	25.9% (23.8%; 28.2%)
	I	803	87.3% (84.7%; 89.9%)	73.3% (69.7%; 77.1%)	64.5% (60.3%; 69.0%)	314	78.7% (74.1%; 83.7%)	69.1% (63.4%; 75.3%)	58.7% (52.4%; 65.8%)
	II	709	71.1% (67.7%; 74.8%)	41.9% (38.1%; 46.1%)	34.6% (30.8%; 38.9%)	276	65.3% (59.7%; 71.4%)	42.6% (36.8%; 49.3%)	32.8% (27.2%; 39.4%)

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	1,630	67.0% (64.7%; 69.4%)	36.5% (34.1%; 39.1%)	29.1% (26.7%; 31.6%)	466	60.5% (56.1%; 65.3%)	34.7% (30.4%; 39.5%)	28.5% (24.4%; 33.4%)
	IV	1,715	36.7% (34.4%; 39.1%)	9.5% (8.1%; 11.0%)	6.2% (5.1%; 7.6%)	456	33.0% (28.9%; 37.7%)	10.4% (7.9%; 13.6%)	6.2% (4.3%; 9.1%)
	X/NA	814	38.3% (35.0%; 41.9%)	18.8% (16.1%; 22.0%)	13.7% (11.1%; 16.8%)	417	38.5% (33.9%; 43.7%)	17.0% (13.4%; 21.4%)	15.4% (11.9%; 19.9%)
2019-2023	All	5,912	61.2% (59.9%; 62.5%)	35.7% (34.3%; 37.1%)	28.7% (27.1%; 30.4%)	2,015	56.9% (54.7%; 59.2%)	37.3% (35.0%; 39.8%)	33.0% (30.4%; 35.9%)
	I	832	89.4% (87.0%; 91.8%)	77.3% (73.6%; 81.1%)	67.0% (61.5%; 73.1%)	269	85.6% (81.2%; 90.3%)	74.7% (68.4%; 81.5%)	71.6% (63.6%; 80.7%)
	II	592	73.3% (69.6%; 77.3%)	47.4% (42.9%; 52.5%)	39.3% (34.0%; 45.4%)	343	65.2% (60.1%; 70.7%)	45.6% (40.0%; 52.1%)	37.3% (31.0%; 45.0%)
	III	1,576	71.2% (68.9%; 73.6%)	42.0% (39.3%; 44.9%)	33.8% (30.6%; 37.3%)	487	69.7% (65.6%; 74.2%)	43.0% (38.4%; 48.2%)	37.8% (32.3%; 44.2%)
	IV	2,304	45.3% (43.2%; 47.4%)	16.1% (14.5%; 17.9%)	10.5% (8.8%; 12.5%)	601	37.2% (33.4%; 41.3%)	14.8% (11.9%; 18.3%)	13.0% (10.1%; 16.8%)
	X/NA	638	46.8% (43.0%; 51.0%)	26.4% (22.7%; 30.7%)	22.4% (18.4%; 27.3%)	323	42.5% (37.3%; 48.6%)	32.1% (26.7%; 38.5%)	27.9% (21.4%; 36.4%)

5.2. Oesophageal cancer survival trends: by tumour type and tumour stage

5.2.1. Oesophageal cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2023

Type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
Total		All	21,249	57.3% (56.6%; 58.0%)	31.4% (30.7%; 32.1%)	25.2% (24.5%; 25.9%)	7,108	53.8% (52.6%; 55.0%)	32.3% (31.1%; 33.5%)	27.0% (25.8%; 28.2%)
ADC	2004-2008	All	2,725	58.0% (56.1%; 60.0%)	31.6% (29.8%; 33.6%)	26.1% (24.3%; 28.0%)	648	50.3% (46.4%; 54.4%)	26.7% (23.3%; 30.7%)	20.9% (17.6%; 24.8%)
		I	454	87.9% (84.6%; 91.4%)	76.1% (71.5%; 81.1%)	70.8% (65.5%; 76.6%)	112	81.8% (74.3%; 90.0%)	68.0% (58.7%; 78.9%)	64.6% (54.1%; 77.2%)
		II	423	73.6% (69.2%; 78.2%)	43.7% (38.8%; 49.2%)	36.6% (31.7%; 42.3%)	104	58.7% (49.6%; 69.5%)	28.1% (20.2%; 39.1%)	20.3% (13.3%; 30.9%)
		III	528	65.9% (61.9%; 70.3%)	28.3% (24.5%; 32.6%)	21.1% (17.6%; 25.3%)	122	60.1% (51.9%; 69.7%)	28.4% (21.2%; 38.0%)	20.9% (14.5%; 30.0%)
		IV	726	40.6% (37.1%; 44.4%)	9.0% (7.1%; 11.5%)	5.7% (4.1%; 7.8%)	112	29.9% (22.5%; 39.8%)	6.7% (3.4%; 13.2%)	2.1% (0.6%; 6.9%)
		X/NA	594	38.4% (34.6%; 42.8%)	19.5% (16.2%; 23.4%)	13.6% (10.6%; 17.4%)	198	33.6% (27.4%; 41.2%)	13.3% (9.0%; 19.8%)	7.3% (4.1%; 13.2%)
	2009-2013	All	3,290	59.9% (58.2%; 61.7%)	32.3% (30.6%; 34.1%)	26.2% (24.6%; 28.0%)	769	55.7% (52.1%; 59.5%)	28.9% (25.6%; 32.7%)	25.6% (22.2%; 29.5%)
		I	596	88.0% (85.1%; 91.1%)	76.6% (72.4%; 80.9%)	70.2% (65.4%; 75.4%)	119	83.3% (76.0%; 91.3%)	67.6% (57.8%; 78.9%)	65.9% (55.2%; 78.8%)
		II	450	72.3% (68.0%; 76.8%)	42.3% (37.6%; 47.5%)	34.1% (29.5%; 39.5%)	120	64.6% (56.3%; 74.2%)	36.4% (28.2%; 47.1%)	30.1% (22.3%; 40.8%)
		III	904	67.4% (64.3%; 70.7%)	31.7% (28.6%; 35.1%)	24.0% (21.1%; 27.3%)	174	65.7% (58.8%; 73.5%)	31.9% (25.4%; 40.1%)	27.7% (21.3%; 35.9%)
		IV	838	39.0% (35.8%; 42.5%)	7.1% (5.5%; 9.1%)	3.4% (2.3%; 4.9%)	162	38.4% (31.5%; 46.7%)	9.9% (6.2%; 15.9%)	5.8% (3.0%; 11.0%)
		X/NA	502	36.8% (32.6%; 41.5%)	14.0% (11.0%; 17.8%)	9.0% (6.5%; 12.5%)	194	38.8% (32.1%; 46.9%)	13.8% (9.2%; 20.8%)	12.8% (7.9%; 20.8%)
	2014-2018	All	3,732	59.8% (58.1%; 61.4%)	33.8% (32.2%; 35.5%)	28.4% (26.8%; 30.1%)	885	54.4% (51.0%; 57.9%)	31.9% (28.7%; 35.4%)	26.3% (23.2%; 29.8%)
		I	585	89.5% (86.6%; 92.4%)	79.9% (75.8%; 84.3%)	74.0% (69.0%; 79.4%)	141	86.5% (80.4%; 93.1%)	80.8% (72.7%; 89.8%)	73.5% (63.8%; 84.6%)
		II	392	75.4% (70.9%; 80.2%)	45.4% (40.2%; 51.2%)	40.1% (34.7%; 46.2%)	92	69.2% (60.0%; 79.8%)	47.7% (37.8%; 60.1%)	41.2% (31.3%; 54.3%)
		III	1,095	70.0% (67.2%; 72.9%)	38.9% (35.9%; 42.1%)	32.2% (29.3%; 35.5%)	239	63.9% (57.9%; 70.6%)	35.7% (29.7%; 42.8%)	28.6% (22.9%; 35.9%)
		IV	1,250	39.8% (37.1%; 42.6%)	10.4% (8.7%; 12.3%)	6.7% (5.4%; 8.4%)	258	37.4% (31.9%; 43.9%)	11.1% (7.8%; 15.8%)	5.3% (3.0%; 9.1%)
		X/NA	410	36.0% (31.4%; 41.2%)	14.6% (11.1%; 19.1%)	8.1% (5.4%; 12.2%)	155	29.8% (23.1%; 38.4%)	6.9% (3.6%; 13.4%)	6.1% (2.9%; 13.0%)
	2019-2023	All	4,075	64.1% (62.5%; 65.6%)	37.5% (35.8%; 39.3%)	31.1% (29.1%; 33.2%)	868	58.9% (55.5%; 62.4%)	35.6% (32.1%; 39.5%)	31.4% (27.4%; 36.0%)

Type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		I	632	92.2% (89.6%; 94.8%)	82.6% (78.5%; 86.9%)	75.4% (69.1%; 82.2%)	118	95.7% (91.1%; 100.6%)	83.8% (75.1%; 93.4%)	84.3% (73.1%; 97.3%)
		II	286	78.6% (73.5%; 84.1%)	53.5% (46.7%; 61.3%)	48.3% (40.3%; 57.8%)	85	68.6% (58.6%; 80.3%)	45.5% (34.3%; 60.4%)	36.2% (24.0%; 54.6%)
		III	1,132	74.0% (71.3%; 76.8%)	44.3% (41.0%; 47.8%)	37.1% (33.4%; 41.3%)	249	74.0% (68.4%; 80.1%)	43.7% (37.2%; 51.4%)	36.2% (27.9%; 46.9%)
		IV	1,799	48.7% (46.3%; 51.1%)	17.5% (15.6%; 19.6%)	11.2% (9.3%; 13.5%)	341	38.7% (33.8%; 44.4%)	14.7% (11.0%; 19.7%)	12.1% (8.4%; 17.4%)
		X/NA	228	40.4% (34.3%; 47.7%)	15.8% (11.0%; 22.7%)	10.5% (6.3%; 17.6%)	75	31.5% (22.1%; 45.0%)	17.4% (9.9%; 30.6%)	7.7% (2.4%; 25.1%)
SCC	2004-2008	All	1,617	48.2% (45.8%; 50.8%)	22.2% (20.2%; 24.4%)	15.8% (14.0%; 17.8%)	740	48.7% (45.1%; 52.5%)	27.0% (23.9%; 30.6%)	21.8% (18.8%; 25.3%)
		I	102	86.9% (80.1%; 94.1%)	65.1% (55.9%; 76.0%)	51.4% (41.4%; 63.8%)	53	91.9% (84.3%; 100.2%)	77.0% (65.6%; 90.5%)	74.0% (61.5%; 88.9%)
		II	293	62.7% (57.3%; 68.7%)	37.3% (32.0%; 43.7%)	28.2% (23.2%; 34.4%)	153	66.7% (59.4%; 75.0%)	41.0% (33.5%; 50.3%)	35.1% (27.6%; 44.7%)
		III	383	49.7% (44.8%; 55.1%)	21.8% (17.9%; 26.5%)	14.2% (11.0%; 18.4%)	158	55.4% (48.0%; 63.8%)	34.9% (28.0%; 43.5%)	23.5% (17.3%; 31.8%)
		IV	352	40.1% (35.3%; 45.7%)	8.9% (6.3%; 12.5%)	5.2% (3.3%; 8.2%)	138	42.0% (34.5%; 51.2%)	9.4% (5.5%; 15.8%)	5.4% (2.6%; 11.2%)
		X/NA	487	36.1% (32.0%; 40.7%)	14.0% (11.1%; 17.6%)	9.8% (7.4%; 13.1%)	238	26.8% (21.6%; 33.3%)	11.9% (8.3%; 17.1%)	10.1% (6.7%; 15.3%)
	2009-2013	All	1,695	49.9% (47.5%; 52.4%)	25.0% (22.9%; 27.2%)	18.0% (16.2%; 20.1%)	843	53.4% (50.0%; 56.9%)	32.9% (29.8%; 36.4%)	27.1% (24.0%; 30.6%)
		I	187	76.7% (70.6%; 83.4%)	53.4% (46.3%; 61.7%)	46.0% (38.6%; 54.7%)	108	84.3% (77.3%; 92.0%)	73.4% (64.5%; 83.6%)	65.2% (55.0%; 77.3%)
		II	290	68.0% (62.6%; 73.8%)	37.6% (32.1%; 43.9%)	28.8% (23.7%; 35.0%)	175	62.6% (55.7%; 70.4%)	41.3% (34.4%; 49.7%)	36.4% (29.5%; 44.9%)
		III	509	54.5% (50.3%; 59.1%)	26.2% (22.5%; 30.5%)	18.7% (15.4%; 22.7%)	227	63.0% (56.9%; 69.8%)	35.7% (29.8%; 42.8%)	26.8% (21.3%; 33.5%)
		IV	331	31.1% (26.4%; 36.5%)	9.1% (6.5%; 12.9%)	4.6% (2.8%; 7.6%)	133	31.4% (24.4%; 40.4%)	10.9% (6.6%; 17.8%)	7.9% (4.4%; 14.2%)
		X/NA	378	33.0% (28.5%; 38.2%)	13.6% (10.5%; 17.7%)	7.1% (4.8%; 10.6%)	200	32.2% (26.2%; 39.6%)	15.3% (10.8%; 21.6%)	11.6% (7.6%; 17.7%)
	2014-2018	All	1,703	53.2% (50.8%; 55.7%)	27.2% (25.1%; 29.5%)	19.3% (17.4%; 21.4%)	922	51.3% (48.1%; 54.7%)	31.4% (28.5%; 34.7%)	24.8% (22.0%; 27.9%)
		I	213	81.4% (76.0%; 87.1%)	56.2% (49.4%; 63.8%)	38.9% (32.4%; 46.8%)	165	72.8% (66.1%; 80.2%)	59.1% (51.6%; 67.8%)	46.6% (38.7%; 56.0%)
		II	305	66.1% (60.8%; 71.8%)	36.9% (31.6%; 43.2%)	26.8% (21.8%; 32.9%)	178	63.7% (56.9%; 71.5%)	40.3% (33.4%; 48.7%)	28.4% (22.1%; 36.5%)
		III	518	60.7% (56.6%; 65.2%)	31.2% (27.3%; 35.6%)	22.5% (18.9%; 26.6%)	220	56.5% (50.3%; 63.6%)	33.4% (27.6%; 40.4%)	28.0% (22.4%; 34.9%)
		IV	411	30.3% (26.1%; 35.2%)	7.7% (5.5%; 10.9%)	5.1% (3.3%; 7.9%)	184	28.2% (22.3%; 35.5%)	10.1% (6.5%; 15.6%)	8.0% (4.9%; 13.3%)
		X/NA	256	36.1% (30.5%; 42.6%)	14.9% (11.0%; 20.2%)	10.5% (7.1%; 15.4%)	175	35.9% (29.3%; 43.9%)	16.3% (11.5%; 23.1%)	14.2% (9.6%; 20.9%)

Type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	2019-2023	All	1,591	55.5% (53.0%; 58.1%)	31.4% (28.9%; 34.0%)	22.3% (19.5%; 25.5%)	1,009	55.6% (52.6%; 58.9%)	37.8% (34.6%; 41.2%)	32.7% (29.2%; 36.6%)
		I	196	80.0% (74.3%; 86.2%)	59.5% (52.0%; 68.2%)	37.2% (27.5%; 50.3%)	148	77.3% (70.5%; 84.6%)	66.9% (58.4%; 76.7%)	58.5% (47.2%; 72.6%)
		II	306	68.4% (63.2%; 74.1%)	41.8% (35.9%; 48.5%)	30.9% (24.4%; 39.2%)	258	64.0% (58.2%; 70.4%)	45.7% (39.4%; 53.0%)	37.6% (30.5%; 46.2%)
		III	442	64.0% (59.5%; 68.8%)	36.0% (31.3%; 41.4%)	24.8% (19.5%; 31.4%)	237	65.6% (59.6%; 72.1%)	42.4% (36.1%; 49.9%)	39.0% (32.2%; 47.2%)
		IV	502	33.2% (29.3%; 37.7%)	10.9% (8.3%; 14.5%)	7.8% (5.0%; 12.0%)	259	34.9% (29.5%; 41.3%)	15.0% (10.9%; 20.5%)	14.3% (10.1%; 20.0%)
		X/NA	145	46.0% (38.3%; 55.1%)	27.4% (20.2%; 37.1%)	23.7% (16.0%; 35.2%)	108	34.1% (26.1%; 44.6%)	23.8% (16.4%; 34.6%)	14.4% (7.6%; 27.2%)
Other and unspecified	2004-2008	All	203	45.9% (39.3%; 53.5%)	24.4% (18.8%; 31.6%)	24.0% (18.1%; 31.7%)	90	47.7% (38.3%; 59.5%)	33.4% (24.6%; 45.3%)	30.6% (21.7%; 43.0%)
		I	11	N<50	N<50	N<50	5	N<50	N<50	N<50
		II	21	N<50	N<50	N<50	5	N<50	N<50	N<50
		III	29	N<50	N<50	N<50	11	N<50	N<50	N<50
		IV	59	29.6% (20.0%; 43.8%)	5.7% (2.1%; 15.4%)	6.2% (2.3%; 16.7%)	19	N<50	N<50	N<50
		X/NA	83	47.6% (37.8%; 60.1%)	34.2% (24.7%; 47.2%)	33.1% (23.2%; 47.4%)	50	51.4% (39.0%; 67.7%)	45.5% (32.9%; 62.9%)	42.1% (29.2%; 60.9%)
	2009-2013	All	193	44.2% (37.6%; 52.1%)	25.0% (19.3%; 32.5%)	23.6% (17.8%; 31.3%)	91	62.4% (52.7%; 73.8%)	42.6% (32.7%; 55.5%)	38.8% (28.3%; 53.4%)
		I	12	N<50	N<50	N<50	8	N<50	N<50	N<50
		II	14	N<50	N<50	N<50	6	N<50	N<50	N<50
		III	30	N<50	N<50	N<50	7	N<50	N<50	N<50
		IV	53	17.0% (9.4%; 30.5%)	4.4% (1.3%; 14.3%)	4.5% (1.4%; 14.8%)	10	N<50	N<50	N<50
		X/NA	84	52.7% (42.6%; 65.1%)	35.7% (26.2%; 48.6%)	32.7% (23.1%; 46.4%)	60	65.5% (53.9%; 79.5%)	55.5% (43.0%; 71.7%)	51.1% (37.1%; 70.3%)
	2014-2018	All	237	43.5% (37.5%; 50.5%)	30.5% (24.7%; 37.5%)	28.2% (22.2%; 35.8%)	124	54.7% (46.4%; 64.5%)	34.8% (26.8%; 45.2%)	31.5% (23.3%; 42.6%)
		I	5	N<50	N<50	N<50	9	N<50	N<50	N<50
		II	12	N<50	N<50	N<50	6	N<50	N<50	N<50
		III	17	N<50	N<50	N<50	7	N<50	N<50	N<50
		IV	54	13.3% (6.9%; 25.9%)	2.2% (0.5%; 10.2%)	2.6% (0.6%; 12.0%)	14	N<50	N<50	N<50

Type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		X/NA	149	49.0% (41.4%; 58.1%)	37.2% (29.6%; 46.8%)	34.7% (26.7%; 45.2%)	88	58.6% (48.9%; 70.2%)	35.7% (26.3%; 48.6%)	33.9% (24.1%; 47.7%)
	2019-2023	All	276	54.1% (48.3%; 60.6%)	36.6% (30.7%; 43.7%)	33.5% (26.9%; 41.8%)	145	55.9% (48.2%; 64.8%)	47.9% (39.4%; 58.1%)	50.5% (38.7%; 65.9%)
		I	4	N<50	N<50	N<50	3	N<50	N<50	N<50
		III	4	N<50	N<50	N<50	1	N<50	N<50	N<50
		IV	3	N<50	N<50	N<50	1	N<50	N<50	N<50
		X/NA	265	52.8% (46.9%; 59.5%)	35.2% (29.3%; 42.4%)	31.9% (25.3%; 40.4%)	140	55.0% (47.1%; 64.1%)	47.4% (38.8%; 57.8%)	49.9% (37.9%; 65.7%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6. CANCER MORTALITY



6.1. Oesophageal cancer mortality: by region

6.1.1. *Oesophageal cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021*

N [CR]																						ESR2013 (95%CI)	
Region	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages		
Males																							
Belgium	0	0	0	0	1	1	1	0	5	14	16	44	77	85	108	86	65	46	18	3	570	11.0	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.3]	[0.0]	[1.3]	[3.7]	[4.0]	[10.9]	[21.2]	[27.7]	[40.7]	[49.4]	[49.7]	[59.2]	[64.1]	[55.0]	[10.0]	(10.0; 11.9)	
Brussels	0	0	0	0	0	0	0	0	0	1	2	3	8	5	5	5	4	0	0	0	33	8.6	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[5.0]	[8.8]	[29.3]	[24.1]	[29.9]	[43.5]	[47.3]	[0.0]	[0.0]	[0.0]	[5.5]	(5.6; 11.6)	
Flanders	0	0	0	0	1	0	1	0	4	10	11	30	53	50	71	62	48	38	13	2	394	12.1	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.5]	[0.0]	[1.9]	[4.7]	[4.7]	[12.3]	[24.0]	[26.6]	[43.8]	[54.3]	[55.6]	[73.5]	[70.9]	[55.9]	[12.0]	(10.9; 13.3)	
Wallonia	0	0	0	0	0	1	0	0	1	3	3	11	16	30	32	19	13	8	5	1	143	9.1	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[0.9]	[2.4]	[2.4]	[8.8]	[13.9]	[30.7]	[37.0]	[39.2]	[36.2]	[38.2]	[66.0]	[71.1]	[8.0]	(7.6; 10.6)	
Females																							
Belgium	0	0	0	0	0	1	0	0	0	2	4	8	23	33	24	35	20	20	8	8	186	2.9	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.0]	[0.0]	[0.5]	[1.0]	[2.0]	[6.2]	[10.1]	[8.1]	[16.4]	[10.8]	[14.8]	[12.1]	[41.6]	[3.2]	(2.5; 3.3)	
Brussels	0	0	0	0	0	1	0	0	0	0	0	1	1	0	3	2	2	1	0	0	11	2.2	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.0]	[3.4]	[0.0]	[13.9]	[12.3]	[14.6]	[9.8]	[0.0]	[0.0]	[1.8]	(0.9; 3.5)	

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	0	0	0	0	0	0	0	2	2	4	9	24	15	23	17	14	7	1	118	3.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[0.9]	[1.7]	[4.1]	[12.4]	[8.6]	[17.3]	[14.6]	[16.5]	[17.5]	[8.9]	[3.5]	(2.5; 3.6)
Wallonia	0	0	0	0	0	0	0	0	0	0	2	3	13	9	6	10	1	5	1	7	57	2.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.6]	[2.4]	[10.7]	[8.3]	[6.0]	[15.7]	[1.8]	[12.5]	[4.9]	[115.9]	[3.1]	(2.1; 3.5)

Note: Mortality, as registered with ICD-10 C15.

7. CANCER MORTALITY TRENDS



7.1. Oesophageal cancer mortality trends: by region

7.1.1. Oesophageal cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	N	487	464	460	499	515	495	540	497	514	589	563	554	586	539	560	605	565	570	-0.3 (-0.7; 0.1)	2004-2021
	CR	9.6	9.1	8.9	9.6	9.9	9.4	10.2	9.3	9.5	10.8	10.3	10.1	10.6	9.7	10.0	10.7	10.0	10.0		
	ESR2013	12.3	11.2	11.5	11.7	12.0	11.5	12.5	11.3	11.2	12.6	12.3	11.4	11.9	11.1	11.2	12.0	11.0	11.0		
Brussels	N	34	39	33	33	33	36	46	35	26	29	44	35	23	31	19	43	34	33	-2.0 (-4.2; 0.2)	2004-2021
	CR	7.1	8.1	6.7	6.6	6.5	7.0	8.7	6.5	4.7	5.2	7.8	6.1	4.0	5.3	3.2	7.3	5.7	5.5		
	ESR2013	10.8	11.8	10.2	9.5	10.1	11.8	13.3	10.0	7.2	8.3	13.3	10.4	6.4	8.7	5.1	11.7	8.7	8.6		
Flanders	N	294	255	281	301	324	302	333	303	324	377	354	343	378	343	365	402	364	394	0.2 (-0.4; 0.9)	2004-2021
	CR	9.9	8.6	9.4	10.0	10.7	9.9	10.8	9.7	10.3	12.0	11.2	10.8	11.8	10.6	11.3	12.3	11.1	12.0		
	ESR2013	12.5	10.2	11.4	11.5	12.3	11.5	12.8	11.2	11.6	13.1	12.5	11.3	12.4	11.4	11.9	12.8	11.3	12.1		
Wallonia	N	159	170	146	165	158	157	161	159	164	183	165	176	185	165	176	160	167	143	-1.7 (-2.3; -1.2)	2004-2021
	CR	9.7	10.3	8.8	9.9	9.4	9.3	9.5	9.3	9.5	10.6	9.5	10.1	10.5	9.4	9.9	9.0	9.4	8.0		
	ESR2013	12.3	13.0	12.1	12.6	12.0	11.4	11.8	12.0	11.2	12.6	11.4	11.8	12.3	11.1	11.3	10.5	10.7	9.1		
																				-0.7 (-1.2; -0.3)	2004-2019
																				-8.7 (-13.1; -4.1)	2020-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Note: Mortality, as registered with ICD-10 C15.

7.1.2. Oesophageal cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	N	172	175	171	188	167	182	195	187	201	179	209	201	207	199	179	226	183	186	-0.5 (-1.1; 0.2)	2004-2021
	CR	3.2	3.3	3.2	3.5	3.1	3.3	3.5	3.4	3.6	3.2	3.7	3.5	3.6	3.5	3.1	3.9	3.1	3.2		
	ESR2013	3.4	3.3	3.2	3.4	3.0	3.3	3.4	3.2	3.4	2.9	3.4	3.4	3.2	3.3	2.8	3.6	2.8	2.9		
Brussels	N	24	17	17	23	23	18	20	14	23	14	15	17	25	15	15	16	16	11	-2.8 (-4.7; -0.9)	2004-2021
	CR	4.6	3.2	3.2	4.3	4.2	3.3	3.6	2.4	3.9	2.4	2.5	2.8	4.1	2.5	2.5	2.6	2.6	1.8		
	ESR2013	5.0	3.7	3.6	4.7	4.7	3.6	4.3	2.7	4.0	2.5	3.1	3.6	5.1	2.8	2.7	3.3	3.0	2.2		
Flanders	N	83	99	99	103	86	94	113	110	110	105	107	110	98	119	100	140	109	118	-0.1 (-1.0; 0.8)	2004-2021
	CR	2.7	3.2	3.2	3.3	2.8	3.0	3.6	3.4	3.4	3.3	3.3	3.4	3.0	3.6	3.0	4.2	3.3	3.5		
	ESR2013	2.8	3.2	3.2	3.1	2.7	2.9	3.3	3.2	3.1	2.9	2.9	3.0	2.5	3.2	2.6	3.7	2.7	3.1		
Wallonia	N	65	59	55	62	58	70	62	63	68	60	87	74	84	65	64	70	58	57	-1.2 (-2.3; -0.2)	2004-2021
	CR	3.7	3.4	3.1	3.5	3.3	3.9	3.4	3.5	3.7	3.3	4.7	4.0	4.6	3.5	3.5	3.8	3.1	3.1		
	ESR2013	3.9	3.4	3.2	3.5	3.3	4.0	3.4	3.4	3.6	3.1	4.5	3.9	4.1	3.5	3.3	3.5	2.9	2.8		
																				0.8 (-0.5; 2.1)	2004-2017
																				-7.5 (-12.0; -2.7)	2018-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Note: Mortality, as registered with ICD-10 C15.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Mortality is reported by main group of ICD-10 classification.

Recommended reference: Cancer Fact Sheets 2023, Belgian Cancer Registry (BCR), 2025